Antimicrobial peptide (Cn-AMP2) from liquid endosperm of Cocos nucifera forms amyloid-like fibrillar structure

Journal of Peptide Science

Volumn 22, Issue 4, 2016, Pages 201-207

  Gour, Shalini ^a   Kaushik, Vibha ^a   Kumar, Vijay ^a   Bhat, Priyanka ^a   Yadav, Subhash C ^b   Yadav, Jay K ^a  

^a CENTRAL UNIVERSITY OF RAJASTHAN   (India)

^b ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

Author keywords

amyloids; antimicrobial peptides (AMPs); cross structure; oligomers

Indexed keywords

AMINO ACID; AMYLOID; AMYLOID BETA PROTEIN; ANTIMICROBIAL PEPTIDE 2; BUFFER; CONGO RED; POLYPEPTIDE ANTIBIOTIC AGENT; THIOFLAVINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; PLANT PROTEIN; PROTEIN AGGREGATE;

ABSORPTION; ARTICLE; BETA SHEET; COCONUT; COCONUT MILK; COMPUTER MODEL; CONTROLLED STUDY; FLUORESCENCE; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN STRUCTURE; SOLUBILIZATION; TRANSMISSION ELECTRON MICROSCOPY; CHEMISTRY; ENDOSPERM; PROTEIN QUATERNARY STRUCTURE; PROTEIN SECONDARY STRUCTURE; ULTRASTRUCTURE;

AMYLOID; ANTI-INFECTIVE AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; COCOS; ENDOSPERM; PLANT PROTEINS; PROTEIN AGGREGATES; PROTEIN STRUCTURE, QUATERNARY; PROTEIN STRUCTURE, SECONDARY;

EID: 84959540408     PISSN: 10752617     EISSN: 10991387     Source Type: Journal    
DOI: 10.1002/psc.2860     Document Type: Article

References (52)

1. Kumar S,. Mechanisms of amyloid fibril formation by proteins. Curr. Sci. 2010; 98: 639-656.
2. Selkoe DJ,. Folding proteins in fatal ways. Nature 2003; 426: 900-904.
3. Cohen FE, Kelly JW,. Therapeutic approaches to protein-misfolding diseases. Nature 2003; 426: 905-909.
4. Westermark P, Andersson A, Westermark GT,. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol. Rev. 2011; 91: 795-826.
5. Verma M, Vats A, Taneja V,. Toxic species in amyloid disorders: oligomers or mature fibrils. Ann. Indian Acad. Neuro. 2015; 18: 138-145.
6. Uversky VN,. Mysterious oligomerization of the amyloidogenic proteins. FEBS J. 2010; 277: 2940-2953.
7. Sakono M, Zako T,. Amyloid oligomers: formation and toxicity of Aβ oligomers. FEBS J. 2010; 277: 1348-1358.
8. Zhang M, Zhao J, Zheng J,. Molecular understanding of a potential functional link between antimicrobial and amyloid peptides. Soft Matter 2014; 10: 7425-7451.
9. Kourie JI, Culverson AL, Farrelly PV, Henry CL, Laohachai KN,. Heterogeneous amyloid-formed ion channels as a common cytotoxic mechanism: implications for therapeutic strategies against amyloidosis. Cell Biochem. Biophys. 2002; 36: 191-207.
10. Zasloff M,. Antimicrobial peptides of multicellular organisms. Nature 2002; 415: 389-395.
11. Brandenburg LO, Merres J, Albrecht LJ, Varoga D, Pufe T,. Antimicrobial peptides: multifunctional drugs for different applications. Polymers 2012; 4: 539-560.
12. Brogden KA,. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005; 3: 238-250.
13. Jang H, Arce FT, Mustata M, Ramachandran S, Capone R, Nussinov R, Lal R,. Antimicrobial protegrin-1 forms amyloid-like fibrils with rapid kinetics suggesting a functional link. Biophys. J. 2011; 100: 1775-1783.
14. Yeaman MR, Yount NY,. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003; 55: 27-55.
15. Matsuzaki K,. Control of cell selectivity of antimicrobial peptides. Biochim. Biophys. Acta 1788; 2009: 1687-1692.
16. Seo MD, Won HS, Kim JH, Mishig-Ochir T, Lee BJ,. Antimicrobial peptides for therapeutic applications: a review. Molecules 2012; 17: 12276-12286.
17. Nguyen LT, Haney EF, Vogel HJ,. The expanding scope of antimicrobial peptide structures and their modes of action. Trends Biotechnol. 2011; 29: 464-472.
18. Teixeira V, Feio MJ, Bastos M,. Role of lipids in the interaction of antimicrobial peptides with membranes. Prog. Lipid Res. 2012; 51: 149-177.
19. Huang Y, Huang J, Chen Y,. Alpha-helical cationic antimicrobial peptides: relationships of structure and function. Protein Cell 2010; 1: 143-152.
20. Shai Y, Oren Z,. From «carpet» mechanism to de-novo designed diastereomeric cell-selective antimicrobial peptides. Peptides 2001; 22: 1629-1641.
21. Rotem S, Mor A,. Antimicrobial peptide mimics for improved therapeutic properties. Biochim. Biophys. Acta 1788; 2009: 1582-1592.
22. Hancock RE,. The bacterial outer membrane as a drug barrier. Trends Microbiol. 1997; 5: 37-42.
23. Hancock RE, Sahl HG,. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006; 24: 1551-1557.
24. Guilhelmelli F, Vilela N, Albuquerque P, Derengowski Lda S, Silva-Pereira I, Kyaw CM,. Antibiotic development challenges: the various mechanisms of action of antimicrobial peptides and of bacterial resistance. Front. Microbiol. 2013; 4: 1-12.
25. Straus SK, Hancock RE,. Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides. Biochim. Biophys. Acta 1758; 2006: 1215-1223.
26. Landreh M, Johansson J, Jornvall H,. Separate molecular determinants in amyloidogenic and antimicrobial peptides. J. Mol. Biol. 2014; 426: 2159-2166.
27. Eisenberg D, Jucker M,. The amyloid state of proteins in human diseases. Cell 2012; 148: 1188-1203.
28. Kagan BL,. Antimicrobial amyloids? Biophys. J. 2011; 100: 1597-1598.
29. Last NB, Miranker AD,. Common mechanism unites membrane poration by amyloid and antimicrobial peptides. Proc. Natl. Acad. Sci. U. S. A. 2013; 110: 6382-6387.
30. Soscia SJ, Kirby JE, Washicosky KJ, Tucker SM, Ingelsson M, Hyman B, Burton MA, Goldstein LE, Duong S, Tanzi RE, Moir RD,. The Alzheimer's disease-associated amyloid beta-protein is an antimicrobial peptide. PLoS One 2010; 5: e9505.
31. Mandal SM, Dey S, Mandal M, Sarkar S, Maria-Neto S, Franco OL,. Identification and structural insights of three novel antimicrobial peptides isolated from green coconut water. Peptides 2009; 30: 633-637.
32. Gill SC, Von Hippel PH,. Calculation of protein extinction coefficients from amino acid sequence data. Anal. Biochem. 1989; 182: 319-326.
33. Bradford MM,. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976; 72: 248-254.
34. Klunk WE, Pettegrew JW, Abraham DJ,. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J Histochem Cytochem. 1989; 37: 1273-1281.
35. Khurana R, Coleman C, Ionescu-Zanetti C, Carter SA, Krishna V, Grover RK, Roy R, Singh S,. Mechanism of thioflavin T binding to amyloid fibrils. J Struct Biol. 2005; 151: 229-238.
36. Pande VS,. A universal TANGO? Nat. Biotechnol. 2004; 22: 1240-1241.
37. Conchillo-Sole O, Groot de NS, Aviles FX, Vendrell J, Daura X, Ventura S,. AGGRESCAN: a server for the prediction and evaluation of «hot spots» of aggregation in polypeptides. BMC Bioinformatics 2007; 8: 65.
38. Garbuzynskiy SO, Lobanov MY, Galzitskaya OV,. FoldAmyloid: a method of prediction of amyloidogenic regions from protein sequence. Bioinformatics 2010; 26: 326-332.
39. Fernandez-Escamilla AM, Rousseau F, Schymkowitz J, Serrano L,. Prediction of sequence-dependent and mutational effects on the aggregation of peptides and proteins. Nat. Biotechnol. 2004; 22: 1302-1306.
40. Thompson MJ, Sievers SA, Karanicolas J, Ivanova MI, Baker D, Eisenberg D,. The 3D profile method for identifying fibril-forming segments of proteins. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 4074-4078.
41. Tsolis AC, Papandreou NC, Iconomidou VA, Hamodrakas SJ,. A consensus method for the prediction of 'aggregation-prone' peptides in globular proteins. PLoS One 2013; 8: e54175.
42. Klunk WE, Pettegrew JW, Abraham DJ,. Quantitative evaluation of congo red binding to amyloid-like proteins with a beta-pleated sheet conformation. J. Histochem. Cytochem. 1989; 37: 1273-1281.
43. Fjell CD, Hiss JA, Hancock RE, Schneider G,. Designing antimicrobial peptides: form follows function. Nat. Rev. Drug Discov. 2012; 11: 37-51.
44. Gordon YJ, Romanowski EG, McDermott AM,. A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs. Curr. Eye Res. 2005; 30: 505-515.
45. Oyston PC, Fox MA, Richards SJ, Clark GC,. Novel peptide therapeutics for treatment of infections. J. Med. Microbiol. 2009; 58: 977-987.
46. Rozek A, Powers JP, Friedrich CL, Hancock RE,. Structure-based design of an indolicidin peptide analogue with increased protease stability. Biochemistry 2003; 42: 14130-14138.
47. Lee IH, Cho Y, Lehrer RI,. Effects of pH and salinity on the antimicrobial properties of clavanins. Infect. Immun. 1997; 65: 2898-2903.
48. John H, Maronde E, Forssmann WG, Meyer M, Adermann K,. N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity. Eur. J. Med. Res. 2008; 13: 73-78.
49. Shorter J,. Hsp104: a weapon to combat diverse neurodegenerative disorders. Neurosignals 2008; 16: 63-74.
50. Nelson R, Eisenberg D,. Structural models of amyloid-like fibrils. Adv. Protein Chem. 2006; 73: 235-282.
51. Scheibel T, Parthasarathy R, Sawicki G, Lin XM, Jaeger H, Lindquist SL,. Conducting nanowires built by controlled self-assembly of amyloid fibers and selective metal deposition. Proc. Natl. Acad. Sci. U. S. A. 2003; 100: 4527-4532.
52. Smith JF, Knowles TP, Dobson CM, Macphee CE, Welland ME,. Characterization of the nanoscale properties of individual amyloid fibrils. Proc. Natl. Acad. Sci. U. S. A. 2006; 103: 15806-15811.